source
- Telix to acquire ITM Isotope for $1.65 billion, targeting radioligand therapy marketTelix Pharmaceuticals announced it will acquire ITM Isotope Technologies Munich for $1.65 billion upfront, securing a radiopharmaceutical supply network. The acquisition brings an R&D pipeline cen…
- Novo presents low-dose CagriSema data showing competitiveness ahead of approval decisionNovo used its capital markets day in London to unveil new low-dose data for its experimental metabolic therapy CagriSema. The data indicated that CagriSema performed comparably to Eli Lilly's Moun…